📊 CINGW Key Takeaways
Is Cingulate Inc. (CINGW) a Good Investment?
Cingulate Inc. is a pre-revenue pharmaceutical company with severe operational losses (-$22.4M net income, -$17.2M operating cash flow) and negative profitability metrics across all dimensions. Despite holding $11.0M in cash, the company is burning cash rapidly with only 7-8 months of runway at current burn rates, creating significant solvency risk without achieving clinical or commercial milestones.
Cingulate’s fundamentals are very weak: it is generating effectively no sustainable revenue, posting deep operating and net losses, and consuming significant cash relative to its asset base. While the company still holds meaningful cash and carries no long-term debt, its thin equity cushion, negative operating cash flow, and severe profitability deficits make the growth profile highly speculative and financially fragile.
Why Buy Cingulate Inc. Stock? CINGW Key Strengths
- Maintains $11.0M cash position providing near-term operational runway
- Low debt burden (0.00x Debt/Equity ratio) with no long-term debt obligations
- Adequate liquidity ratio (1.16x) for immediate operational needs
- Cash balance of $10.95M provides some near-term operating flexibility
- No meaningful long-term debt reduces balance-sheet leverage risk
- Net loss improved year over year, indicating some expense moderation
CINGW Stock Risks: Cingulate Inc. Investment Risks
- Severe cash burn of -$17.2M operating cash flow with only ~7 months cash runway remaining
- Negative revenue (-$1.4M) with complete lack of commercial traction or product sales
- Pre-revenue biotech model with high R&D expenses and no evidence of clinical success or near-term revenue catalysts
- Unsustainable financial structure with consistent quarterly operating losses and negative free cash flow
- High insider trading activity (10 Form 4 filings in 90 days) suggests potential dilution or confidence concerns
- Business remains unprofitable with large operating and net losses and no proven revenue base
- Operating cash outflow and negative free cash flow imply ongoing funding needs if commercialization is delayed
- Very low equity base and negative returns on assets/equity signal weak financial resilience
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway duration
- Clinical trial progress and FDA milestone achievements for lead candidates
- Monthly operating cash flow trend and path to cash flow breakeven
- Insider ownership changes and dilution from future financing rounds
- Revenue recognition from any commercial partnerships or licensing deals
- Quarterly cash burn versus cash balance/runway
- Revenue generation and operating loss trend as products advance toward commercialization
Cingulate Inc. (CINGW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 1,278.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
CINGW Profit Margin, ROE & Profitability Analysis
CINGW vs Healthcare Sector: How Cingulate Inc. Compares
How Cingulate Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cingulate Inc. Stock Overvalued? CINGW Valuation Analysis 2026
Based on fundamental analysis, Cingulate Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cingulate Inc. Balance Sheet: CINGW Debt, Cash & Liquidity
CINGW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cingulate Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-10.86 indicates the company is currently unprofitable.
CINGW Revenue Growth, EPS Growth & YoY Performance
Cingulate Inc. Dividends, Buybacks & Capital Allocation
CINGW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cingulate Inc. (CIK: 0001862150)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CINGW
What is the AI rating for CINGW?
Cingulate Inc. (CINGW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CINGW's key strengths?
Claude: Maintains $11.0M cash position providing near-term operational runway. Low debt burden (0.00x Debt/Equity ratio) with no long-term debt obligations. ChatGPT: Cash balance of $10.95M provides some near-term operating flexibility. No meaningful long-term debt reduces balance-sheet leverage risk.
What are the risks of investing in CINGW?
Claude: Severe cash burn of -$17.2M operating cash flow with only ~7 months cash runway remaining. Negative revenue (-$1.4M) with complete lack of commercial traction or product sales. ChatGPT: Business remains unprofitable with large operating and net losses and no proven revenue base. Operating cash outflow and negative free cash flow imply ongoing funding needs if commercialization is delayed.
What is CINGW's revenue and growth?
Cingulate Inc. reported revenue of $-1.4M.
Does CINGW pay dividends?
Cingulate Inc. does not currently pay dividends.
Where can I find CINGW SEC filings?
Official SEC filings for Cingulate Inc. (CIK: 0001862150) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CINGW's EPS?
Cingulate Inc. has a diluted EPS of $-4.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CINGW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cingulate Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CINGW stock overvalued or undervalued?
Valuation metrics for CINGW: ROE of -894.8% (sector avg: 15%), net margin of 1,649.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CINGW stock in 2026?
Our dual AI analysis gives Cingulate Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CINGW's free cash flow?
Cingulate Inc.'s operating cash flow is $-17.2M, with capital expenditures of $162.1K. FCF margin is 1,278.9%.
How does CINGW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1,649.4% (avg: 12%), ROE -894.8% (avg: 15%), current ratio 1.16 (avg: 2).